From: Post-transplant lymphoproliferative disorder (PTLD): single institutional experience of 141 patients
Therapy type | Sub-type | As 1st line therapy | As 2nd line therapy | As 3rd line therapy | |||
---|---|---|---|---|---|---|---|
n | % | n | % | n | % | ||
Rituximab alone | Â | 35 | 24.8 | 4 | 2.8 | 2 | 1.4 |
Chemotherapy (+Â R) | R-chop | 22 | 15.6 | 11 | 7.8 | 2 | 1.4 |
R/C (cyclophosphamide) | 20 | 14.2 | 5 | 3.5 | Â | Â | |
R-EPOCH | 2 | 1.4 | Â | Â | Â | Â | |
R-CVP | 4 | 2.8 | 2 | 1.4 | 1 | 0.7 | |
BR | 1 | 0.7 | 1 | 0.7 | Â | Â | |
R-hyperCVAD | 1 | 0.7 | Â | Â | Â | Â | |
RICE | 1 | 0.7 | 1 | 0.7 | Â | Â | |
R-Mtx | 1 | 0.7 | Â | Â | Â | Â | |
Chemotherapy (− R) | CHOP | 5 | 3.5 | 1 | 0.7 |  |  |
ABVD | 1 | 0.7 | 1 | 0.7 | Â | Â | |
CVP | 1 | 0.7 | 1 | 0.7 | Â | Â | |
CEOP | 1 | 0.7 | Â | Â | Â | Â | |
Other regimens | 5 | 3.5 | 12 | 8.5 | 8 | 5.7 |